The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.

Slides:



Advertisements
Similar presentations
Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.
Advertisements

Durban, South Africa January 29 to 31, 2013 Topic 8: Compulsory Licenses Regional Seminar for Certain African Countries on the Implementation and Use of.
The TRIPS Agreement and Public Health
Least Developed Countries: IP Needs Assessment: WIPO, WTO and the LDC needs assessment process under TRIPS WIPO Conference on Building Partnerships for.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Regional IPPC Workshops 2014 WTO Agreement on Trade Facilitation (ATF)
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
J.P. Singh Georgetown University Communication, Culture, & Technology Program TRIPS: Negotiating Intellectual Property in the World Trading System J.
RECOMMENDATIONS BY INTELLECTUAL PROPERTY LAWYERS ON LEGAL REFORM MOSES NKOMO LL.B, MIP.
Ato2461 INTELLECTUAL PROPERTY AND DEVELOPMENT Presentation by Adrian Otten Director, Intellectual Property Division, WTO Secretariat Panel Discussion 7.
China on the way to a high-technology country: The legal policy perspective Stefan Luginbuehl Lawyer, International Legal Affairs.
EU: Bilateral Agreements of Member States. Formerly concluded international agreements of Member States with third countries Article 351 TFEU The rights.
Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.
THE WTO TRADE FACILITATION AGREEMENT
Patents in Indian Fisheries Sector  Patents in Indian Fisheries Sector  Living things generally do not qualify for being granted with patents.  If it.
Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,
1 Licensing Agreements and the Protection of Intellectual Property Chapter 17 © 2005 Thomson/West Legal Studies In Business.
Exception to rules on free trade Need to strike a balance between free trade and other values. Member can justify measures incompatible with WTO Agreements.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
TRIMS - Trade Related Investment Measures
Patent Related Flexibilities in the Pharmaceutical Field
FLEXIBILITIES IN WTO’S TRIPS AGREEMENT FOR ACCESS TO MEDICINES
Trade Facilitation in the World Trade Organization Workshop on Capacity Building Programme World Bank Institute Ein El-Sokhna, Egypt April 2004 Mohsen.
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Training Workshop for Regional Advisors Bangkok, Thailand 15 – 27 May 2006.
LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.
The Pharmaceutical Industry in Turkey
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
UNCTAD 1 OVERVIEW OF THE DOHA WORK PROGRAMME ISSUES TO BE CONSIDERED BY DEVELOPING COUNTRIES Commercial Diplomacy Programme UNCTAD
Ten Years of the Doha Declaration: The State of Implementation Geneva 14 November
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Samer Seif El-Yazal - WTO. Bali Ministerial Decision PART II – DOHA DEVELOPMENT AGENDA 1.8 We welcome the progress in the DDA, which is embodied in the.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Data Protection in compliance with Article 39 of the TRIPS Agreement Draft Amendment to the Drugs Act 1976 Humaira Mufti WIPO National Seminar on Flexibilities.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
International Trade Regulations: the Law of the WTO Professor Mohammad F. A. Nsour Class 3 1.
CARTAGENA PROTOCOL ON BIOSAFETY NDA- DEAT BILATERAL MEETING 1 August 2003 Presenter : M. Mbengashe.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN LESOTHO REPORT OF DAY 1 Botha Tiheli, Masello.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur TRIPS – Article.
IMPACT OF THE DOHA DECLARATION November 14, 2011 Carlos M. Correa.
WTO and the TRIPS Agreement Wolf R. MEIER-EWERT WTO Secretariat A Business-oriented overview of Intellectual Property for Law Students WIPO, Geneva 20.
1 Competition policy in WTO sectoral agreements Dr. Pierre Arhel Counsellor (competition policy) Intellectual Property Division Sao Paulo, April.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Durban, South Africa January 29 to 31, 2013 Topic 13: The Effective Administrative Process for the Grant of Compulsory Licenses Regional Seminar for Certain.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
PRESENTATION TO THE SELECT COMMITTEE ON TRADE AND INTERNATIONAL RELATIONS Protocol Amending the Marrakesh Agreement establishing the World Trade Organisation.
International Intellectual Property Prof. Manheim Spring, 2007 Patent Compulsory Licensing Copyright © 2007.
WTO and medicines: from Doha to Cancún
Exception to rules on free trade
Intellectual Property Protection and Access to Medicines
Package of agreements annexed to the WTO Agreement
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.
Béchir N’Daw, UNAIDS Secretariat
29 July 2015 MS. NIKI KRUGER CHIEF DIRECTOR: TRADE NEGOTIATIONS
Acceptance of the Protocol Amending the TRIPS Agreement
PRESENTATION TO THE PORTFOLIO COMMITTEE ON TRADE & INDUSTRY Protocol Amending the Marrakesh Agreement establishing the World Trade Organisation (WTO)
The WTO-Agreement on Trade-Related Investment Measures (TRIMs)
Presentation transcript:

The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO

The Doha Declaration on TRIPS and Public Health (1/3) The Declaration on the TRIPS Agreement and Public Health was adopted on 14 November 2001 during the Ministerial Conference at Doha (Qatar) Main considerations of the Declaration: –the gravity of the public health problems afflicting many developing and least-developed countries –the need for the TRIPS Agreement to be part of the national and international action to address those problems –intellectual property protection is important for the development of new medicines but has effects on their prices –the TRIPS Agreement should not prevent Members from taking measures to protect public health: the Agreement should be interpreted and implemented to support WTO Members' right to protect public health and to promote access to medicines for all

WIPO The Doha Declaration on TRIPS and Public Health (2/3) The Declaration reaffirms the right of WTO Members to use, to the full, the provisions in the TRIPS Agreement, which provide flexibility for this purpose Each provision of the TRIPS Agreement should be read in the light of the object and purpose of the Agreement as expressed in its objectives and principles Flexibilities confirmed to exist already in TRIPS in relation to public health include: –the right to grant compulsory licences and the freedom to determine the grounds for such licences –the right to determine what constitutes a national emergency or other circumstances of extreme urgency –freedom to establish own regime as regards the rule of “exhaustion” of intellectual property rights

WIPO The Doha Declaration on TRIPS and Public Health (3/3) Paragraph 6 of the Doha Declaration - mandate: –the Council for TRIPS was instructed to find an expeditious solution to the problem that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector can face difficulties in making effective use of compulsory licensing Paragraph 7 of the Doha Declaration – extension for LDCs: –extension until 1 January 2016 of transition period for least-developed countries to implement or apply, with respect to pharmaceutical products, TRIPS provisions on patents and on undisclosed information (test data), and to enforce rights under those provisions

WIPO Implementation of paragraph 6 of the Doha Declaration on TRIPS and Public Health Decision of WTO General Council of 30 August 2003: –Set up an interim system for compulsory licensing and exportation of patented pharmaceutical products (or products of a patented pharmaceutical process) –Beneficiaries of system - “eligible importing Members”: any least-developed country any country that has established that it has insufficient or no manufacturing capacities in the pharmaceutical sector for the product in question –Established waivers from the obligations set out in paragraphs (f) and (h) of Article 31 of the TRIPS Agreement with respect to pharmaceutical products. These waivers apply until the amendment of TRIPS comes into force

WIPO Protocol amending the TRIPS Agreement (1/5) Decision of WTO General Council of 6 December 2005: –Adopts a Protocol amending the TRIPS Agreement –The Protocol introduces a new Article 31bis in the TRIPS Agreement and an Annex to the Agreement: they reproduce in substance the system established by the WTO General Council Decision of 30 August 2003 –The Protocol is open for acceptance until 31 December 2009 (as per extension in November 2007) or such later date as may be decided by the Ministerial Conference –The Protocol will take effect upon acceptance by two thirds of the WTO Members (Article X paragraph 3 of the WTO Agreement). To date 11 countries have notified their acceptance

WIPO Protocol amending the TRIPS Agreement (2/5) System under Article 31bis and Annex of TRIPS: –Article 31(f) of TRIPS (requirement that a compulsory licenses must be authorized predominantly to supply the domestic market) does not apply with respect to the grant of a compulsory licence for the purposes of producing a pharmaceutical product and exporting it to an eligible importing country –Article 31(f) of TRIPS does not apply for the purposes of allowing a pharmaceutical product produced or imported into a country under a compulsory license to be exported to other eligible countries in the same regional trade agreement –Article 31(h) of TRIPS (requirement to pay adequate remuneration for a compulsory license) does not apply in respect of products for which remuneration is already paid in the exporting country

WIPO Protocol amending the TRIPS Agreement (3/5) Procedure under Article 31bis and Annex of TRIPS: –Eligible importing country must notify to the Council for TRIPS: the names and expected quantities of the product needed that it has insufficient or no manufacturing capacities in the pharmaceutical sector for the product in question (except LDCs) that, where the product is patented in its territory, it has granted or intends to grant a compulsory licence to import the product –The importing country must take reasonable measures within its means, proportionate to its administrative capacities and to the risk of trade diversion, to prevent re-exportation of the products imported under the system

WIPO Protocol amending the TRIPS Agreement (4/5) Procedure under Article 31bis + Annex of TRIPS: If the product is patented in the exporting country, a compulsory licence may be issued in the exporting country under the following conditions: –only the amount necessary to meet the needs of the importing country may be manufactured and the entirety of this production must be exported to that country –the products produced under the licence must be clearly identified through specific labelling or marking, packaging, colouring or shaping of the products, provided this is feasible and does not have a significant impact on price; and –before shipment begins, the compulsory licensee must post on a website the relevant information The exporting country must notify the Council for TRIPS of the grant of the licence, including the conditions attached to it and contact details of compulsory licensee

WIPO Protocol amending the TRIPS Agreement (5/5) Procedure under Article 31bis + Annex of TRIPS: –All WTO Members must ensure effective legal means to prevent the importation into, and sale in, their territories of products produced under the system and diverted to their markets. If a Member considers that such measures are insufficient, the matter may be reviewed by Council for TRIPS upon request of that Member Cooperation by developed countries: technical cooperation to promote regional patent systems for the purposes of enhancing purchasing power for, and facilitating the local production of, pharmaceutical products technical and financial cooperation in order to facilitate implementation of the system by developing countries or LDCs that encounter difficulty

WIPO Concluding remarks